FMP

FMP

Enter

PACB - Pacific Biosciences ...

photo-url-https://images.financialmodelingprep.com/symbol/PACB.png

Pacific Biosciences of California, Inc.

PACB

NASDAQ

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

1.23 USD

0.04 (3.25%)

Operating Data

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

78.89M

130.51M

128.3M

200.52M

154.01M

191.3M

237.61M

295.12M

366.57M

455.3M

Revenue %

-

65.43

-1.69

56.29

-23.19

24.21

24.21

24.21

24.21

Ebitda

38.97M

-250.76M

-282.24M

-277.28M

-356.38M

-134.14M

-166.61M

-206.94M

-257.04M

-319.26M

Ebitda %

49.4

-192.13

-219.98

-138.28

-231.4

-70.12

-70.12

-70.12

-70.12

Ebit

29.67M

-262.34M

-299.56M

-303.82M

-409.73M

-138.65M

-172.21M

-213.9M

-265.68M

-330M

Ebit %

37.61

-201.01

-233.48

-151.51

-266.04

-72.48

-72.48

-72.48

-72.48

Depreciation

9.3M

11.59M

17.32M

26.53M

53.35M

31.39M

38.99M

48.42M

60.15M

74.71M

Depreciation %

11.79

8.88

13.5

13.23

34.64

16.41

16.41

16.41

16.41

Balance Sheet

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Total Cash

318.81M

1.04B

772.32M

631.42M

389.93M

191.3M

237.61M

295.12M

366.57M

455.3M

Total Cash %

404.11

800.23

601.94

314.89

253.18

100

100

100

100

Receivables

16.84M

24.24M

18.79M

36.62M

27.52M

34.7M

43.1M

53.53M

66.49M

82.58M

Receivables %

21.34

18.57

14.64

18.26

17.87

18.14

18.14

18.14

18.14

Inventories

14.23M

24.6M

50.38M

56.68M

58.76M

54.54M

67.75M

84.15M

104.52M

129.82M

Inventories %

18.04

18.85

39.27

28.26

38.15

28.51

28.51

28.51

28.51

Payable

3.58M

11M

12.03M

15.06M

16.59M

15.54M

19.31M

23.98M

29.78M

36.99M

Payable %

4.54

8.43

9.37

7.51

10.77

8.12

8.12

8.12

8.12

Cap Ex

-1.04M

-5.93M

-16.93M

-8.84M

-6.19M

-10.52M

-13.06M

-16.22M

-20.15M

-25.03M

Cap Ex %

-1.32

-4.54

-13.19

-4.41

-4.02

-5.5

-5.5

-5.5

-5.5

Weighted Average Cost Of Capital

Price

1.23

Beta

Diluted Shares Outstanding

288.37M

Costof Debt

3.72

Tax Rate

After Tax Cost Of Debt

3.72

Risk Free Rate

Market Risk Premium

Cost Of Equity

Total Debt

672.43M

Total Equity

354.69M

Total Capital

1.03B

Debt Weighting

65.47

Equity Weighting

34.53

Wacc

6.82

Build Up Free Cash Flow

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

78.89M

130.51M

128.3M

200.52M

154.01M

191.3M

237.61M

295.12M

366.57M

455.3M

Ebitda

38.97M

-250.76M

-282.24M

-277.28M

-356.38M

-134.14M

-166.61M

-206.94M

-257.04M

-319.26M

Ebit

29.67M

-262.34M

-299.56M

-303.82M

-409.73M

-138.65M

-172.21M

-213.9M

-265.68M

-330M

Tax Rate

-0.1

-0.1

-0.1

-0.1

-0.1

-0.1

-0.1

-0.1

-0.1

-0.1

Ebiat

29.67M

-172.96M

-283.05M

-292.91M

-410.15M

-126.68M

-157.34M

-195.43M

-242.74M

-301.5M

Depreciation

9.3M

11.59M

17.32M

26.53M

53.35M

31.39M

38.99M

48.42M

60.15M

74.71M

Receivables

16.84M

24.24M

18.79M

36.62M

27.52M

34.7M

43.1M

53.53M

66.49M

82.58M

Inventories

14.23M

24.6M

50.38M

56.68M

58.76M

54.54M

67.75M

84.15M

104.52M

129.82M

Payable

3.58M

11M

12.03M

15.06M

16.59M

15.54M

19.31M

23.98M

29.78M

36.99M

Cap Ex

-1.04M

-5.93M

-16.93M

-8.84M

-6.19M

-10.52M

-13.06M

-16.22M

-20.15M

-25.03M

Ufcf

10.45M

-177.66M

-301.96M

-296.31M

-354.45M

-109.81M

-149.26M

-185.39M

-230.27M

-286.01M

Wacc

6.82

6.82

6.82

6.82

6.82

Pv Ufcf

-102.8M

-130.81M

-152.1M

-176.86M

-205.65M

Sum Pv Ufcf

-768.13M

Terminal Value

Growth In Perpetuity Method

Long Term Growth Rate

Wacc

6.82

Free Cash Flow T1

-291.73M

Terminal Value

-6.05B

Present Terminal Value

-4.35B

Intrinsic Value

Enterprise Value

-5.12B

Net Debt

617.06M

Equity Value

-5.73B

Diluted Shares Outstanding

288.37M

Equity Value Per Share

-19.88

Projected DCF

-19.88 1.062%

DCF Levered

Download Excel

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep